We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Magnetic Nanoparticle Tool Developed to Detect MicroRNA

By LabMedica International staff writers
Posted on 12 Sep 2018
Print article
Image: Nucleic acid hybridization on an electrically reconfigurable network of gold-coated magnetic nanoparticles enables microRNA detection in blood (Photo courtesy of University of New South Wales).
Image: Nucleic acid hybridization on an electrically reconfigurable network of gold-coated magnetic nanoparticles enables microRNA detection in blood (Photo courtesy of University of New South Wales).
A magnetic nanoparticle-based technique has been developed to directly detect microRNA (miRNA) in unprocessed whole blood samples in about thirty minutes. Currently scientists use quantitative reverse-transcription polymerase chain reaction (qRT-PCR) to profile miRNA due to its usually high specificity and sensitivity.

Although qRT-PCR produces reliable results, scientists have noted that it does not detect miRNA directly in whole blood. Instead, scientists perform a lengthy process where they must isolate and purify RNA, and then synthesize complementary DNA (cDNA) to measure miRNA expression. The first human disease known to be associated with miRNA deregulation was chronic lymphocytic leukemia.

Scientists at the University of New South Wales (Sydney, Australia) modified the surface of the gold-coated magnetic nanoparticles (Au@MNPs) with a probe DNA sequence complementary to miR-21 and marked it with a blue redox label. The team then added excess network of modified Au@MNPs by probe DNA (DNA-Au@NMPs) to the analyte solution. After 30 minutes, the team magnetically separated the Au@MNPs from the solution and washed away unhybridized sequences. They then collected the Au@MNPs on the surface of a gold microelectrode using a magnet. The team removed the magnet and applied 10 cycles of square-wave voltammetry between 200 and 500 megaVolts, with a pulse amplitude of 20 megavolts and frequency of 2 hertz. The team then used stable peak currents obtained before and after hybridization to measure the amount of analyte.

To examine the electrochemical tool's limit of detection and range of its sensor, the team prepared different concentrations of miR-21 in either phosphate buffered saline (PBS), undiluted human serum, or 50% whole human blood. The group measured a change in the current after 30 minutes of exposure to the miR-21 solutions within the concentration range of 10 attomolar to 1 nanomolar. In order to validate the electrochemical tool, the team used it to analyze miR-21 levels in a pool of other RNA sequences from the total RNA extracted from human lung cancer cells (A459) and exosomes. After treating the samples with an miR-21 inhibitor, the team still detected levels of miR-21 in exosomes eight times lower than the factor of 0.4 in their parental cells.

Using the DNA-Au@MNP-based electrochemical sensor, the team found that the concentration of miR-21 molecules in rapidly growing cancers was higher than those in the "no-control" group. The group also noted that the electrochemical assay had less variability than qRT-PCR. John Gooding, D. Phil, a chemistry professor and senior author of the study, said, “This tool would be especially useful for low levels of certain proteins and molecules, as we could potentially not only diagnose a patient's condition, but also look at treatment efficacy or the potential relapse of a condition like cancer. The study was published on August 27, 2018, in the journal Nature Nanotechnology.

Related Links:
University of New South Wales

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.